Zorevunersen Cuts Convulsive Seizures in Children With Dravet Syndrome

Dravet syndrome is a severe developmental and epileptic encephalopathy driven primarily by loss-of-function variants in the SCN1A gene, which encodes a critical voltage-gated sodium channel [1, 2]. Clinical management relies on symptomatic polytherapy with traditional antiseizure medications, which often fail to achieve seizure freedom and do not address the profound cognitive stagnation, motor impairments, and elevated mortality risk associated with the condition [3, 4]. Because conventional drugs cannot correct the underlying molecular deficit, researchers have increasingly focused on precision therapies, such as antisense oligonucleotides (synthetic nucleic acid strands that bind to specific RNA molecules to alter protein production), to directly modulate gene expression [1, 5]. A newly published phase 1-2a clinical trial of 81 children and adolescents evaluated zorevunersen, an antisense oligonucleotide designed to up-regulate sodium channel production, to determine if it can safely alter the disease trajectory [6]. The study demonstrated that patients receiving up to 70 mg of zorevunersen experienced a median change from baseline in convulsive-seizure frequency ranging from -58.82% to -90.91% over 20 months, offering clinicians a targeted strategy that may improve both seizure control and long-term neurodevelopmental outcomes [6].